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Abstract: Breast cancer (BC) management care requires an increment in quality. An initiative to
improve the BC quality care is registered, and quality indicators (QIs) are studied. We appraised
the appearance of QIs and their standards systematically in Spain. A prospective systematic search
(Prospero no: CRD42021228867) for clinical pathways and integrated breast cancer care processes was
conducted through databases and the World Wide Web in February 2021. Duplicate data extraction
was performed with 98% reviewer agreement. Seventy-four QIs (QI per document mean: 11; standard
deviation: 10.59) were found in 15 documents. The Catalonian document had the highest number of
QIs (n = 30). No QI appeared in all the documents. There were 9/74 QIs covering structure (12.16%),
53/74 covering process (71.62%), and 12/74 covering outcome (16.22%). A total of 22/66 (33.33%)
process and outcome QIs did not set a minimum standard of care. QIs related to primary care, patient
satisfaction, and shared decision making were deficient. Most of the documents established a BC QI
standard for compliance, but the high variability hinders the comparison of outcomes. Establishing a
consensus-based set of QIs needs urgent attention.
Keywords: breast cancer care; quality indicators; quality care; health care; Spanish quality care
1. Introduction
Technological advancement has improved the early detection and treatment of breast
cancer (BC) and has enhanced overall survival [1]. Nowadays, BC care management is
more intricate and requires an increment in quality. An initiative to improve the quality of
BC care is registered, and quality indicators (QIs) are studied [2]. The EUSOMA (European
Society of Breast Cancer Specialists) working group states that “BC QIs provide a set
of metrics to allow centres to follow patients over time in a standardised manner, and
easily recognise when attention is required to improve particular areas of healthcare
delivery” [2]. These must be explained in quality documents for the standardisation of
care as clinical pathways or integrated breast cancer care processes elaborated by official
institutions [3–5]. There are three types of QIs [6]: indicators of structure (evaluates all the
sources used during the provision of services), process (appraises the actions done during
patient care), and outcome (studies the results of patient care) [7,8]. In recent years, patient-
centred care and shared decision making (SDM) (i.e., “a communication process in which
clinicians and patients work together to share the best available evidence, consider options,
and reach decisions about care according to their choices and beliefs”) [9] have gained
importance [10–13]. Thus, there should be QIs focused on the evaluation of SDM [14].
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Numerous authorities have suggested their own sets of QIs to establish BC quality
management evaluation, but no agreement has been reached [15]. For example, in Europe,
EUSOMA [2] has published a compilation of QIs that could be embraced by breast centres
to provide standardised auditing and quality support and to establish an acceptable
minimum standard of care. In Spain, the BC organisation varies among the 16 autonomous
communities. Basic services are respected in all of them, but they establish specific health
plans and adapt resources to the needs of the assigned population [16]. Every autonomous
community has its own document for BC care quality (clinical pathways or integrated
breast cancer assistance processes). These are quality documents deployed to manage
and standardise BC care for a well-defined group of patients during a period of time and
establish structured criteria for quality of care. The variability of this type of documents
makes comparisons of results across populations or hospitals difficult [3,17–22]. There
is also no legal obligation or incentives to report BC care management in public health.
Therefore, BC care quality data analysis is heterogeneous [23].
Our literature search found no reviews about BC management QIs in health adminis-
trations in Europe or Spain. We appraised the appearance of QIs and their standards of
care in Spanish quality documents systematically, paying special attention to the particular
populations to which they are directed and comparing them with those suggested by
EUSOMA [2].
2. Methods
We identified studies through a systematic review of the literature following prospec-
tive registration (Prospero no: CRD42021228867) and reported according to the PRISMA
statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [24,25].
2.1. Data Search and Selection
Eligible studies included clinical pathways and integrated health care processes from
Spanish administrations. The research was performed without language limitations on
online databases (Medline, Web of Science, Embase, and Scopus). The MeSH terms “breast
cancer”, “breast neoplasms”, “quality indicators”, and “quality care” were combined with
other word alternatives in February 2021. The search strategy appears in Appendix A.
Clinical pathways and integrated health care processes are usually not promulgated in
medical journals or indexed. A comprehensive manual search of grey literature was
conducted to find these BC quality documents elaborated by Spanish institutions on the
World Wide Web. We also explored the bibliographies of the papers added to incorporate
other crucial studies to our analysis.
2.2. Study Selection and Data Extraction
Three reviewers (YGF, ARH, and CREL) independently selected studies for inclusion
in the review. The inclusion criteria were integrated breast cancer care processes and
clinical pathways provided by Spanish national institutions. These are quality documents
disposed to guide and standardise BC care for a well-defined group of patients during a
period of time [26] and set structured criteria for quality of care [27]. We only collected
documents that explicitly mentioned BC in a section of writing. We rejected observational
studies, narrative reviews, scientific reports, discussion papers, conference abstracts and
posters, randomised controlled trials (RCTs), clinical practice guidelines, and consensus.
Full-text versions of conceivably relevant citations were obtained to confirm acceptability.
A fourth reviewer (MMC) assisted in solving disagreements by consensus or arbitration.
Where multiple versions were retrieved, the most updated version of the guidelines was
incorporated. Duplicate articles were identified and deleted. We considered the EUSOMA
working group’s position paper [2] as a reference to compare QIs. Data were extracted
from the selected BC QI initiatives in duplicate and independently using standardised
data extraction forms specifically created for this review and subsequently entered into a
database. All data entry was double-checked.
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2.3. Quality Assessment
The reporting of BC QIs from EUSOMA’s position paper [2], the Spanish integrated
cancer care processes and clinical pathways, was independently appraised by three differ-
ent reviewers (YGF, CREL, and ARH) using a piloted data extraction form. No suitable
data extraction form was available for this research topic. We developed a descriptive
quality scoring system that captured all the QIs and specified the document. These QIs
collected in our review have already been validated in the quality documents (clinical
pathways and integrated breast cancer care processes) where they belong. Disparities
among the authors over the risk of bias for particular manuals were solved by group
discussion, requiring a mediator (MMC) who decided when no consensus achieved. Two
QIs were recognised as the same when they measured the same process, even when there
were scanty differences between population targets and minimum standards. All these de-
viations were reported individually in the Results section of this paper. These studied QIs
were classified according to the EUSOMA classification [2] concerning the intervention they
were measuring (diagnosis, treatment, staging, counselling, follow-up, and rehabilitation)
and Donabedian’s framework type (structural, process, and outcome indicators) [6].
2.4. Data Analysis
The inter-rater agreement (ICC) of the data extraction was calculated to assess the
reviewers’ agreement, and ICC >0.90 was considered excellent [28]. A mediator (MMC)
assisted in reaching a consensus and would decide in case of disagreements. We performed
a descriptive statistical study to examine and classify the selected BC QIs using the Stata
15.0 statistical package (StataCorp LLC, College Station, TX, USA).
3. Results
3.1. Study Selection
We identified 1418 relevant references (1165 from databases and 21 from the World
Wide Web and Spanish institutions). Of them, 148 were duplicated reports, and 1255 did
not satisfy the selection criteria. Finally, only 15 Spanish quality documents and the
EUSOMA position paper were evaluated for full-text review [2,29–42]. A PRISMA flow
diagram is synthesised in Figure 1. The study characteristics are reported in Table 1 (year
of publication, organisation, region, evidence analysis used for QI evaluation, type of
document (specific BC document or not), the presence of a specific section on BC, the
appearance of QIs in the document analysed). Table 1 also shows four autonomous
communities from Spain without a quality care document (Balearic and Canary Islands,
Cantabria, and Castile and La Mancha).
3.2. General Quality Indicator Evaluation
There were 85 QIs collected from the quality care documents analysed. The EUSOMA
position paper [2] registered 34/85 QIs (40%). The 51/85 (60%) QIs that did not appear in
the EUSOMA position paper were added after a comprehensive analysis of the Spanish
documents. Only 11/85 (12.94%) QIs appeared only in the EUSOMA paper. Figure 2
shows all the integrated health care programs and clinical pathways studied and the QIs
appearing in them. From the Spanish documents, there were 28/74 QIs related to diagnosis
(37.84%), the same number (28/74) related to treatment (37.84%), and 18/74 (24.32%) QIs
to staging, counselling, follow-up, and rehabilitation. Nine of these Spanish QIs were
structural (12.16%), 53/74 were related to the process (71.62%), and 12/74 were outcome
QIs (16.22%). Analysing EUSOMA indicators that did not appear in any of the Spanish
documents, 2 were related to diagnosis (18.18%), 6/11 related to treatment (54.54%), 1/11
to counselling (9.09%), and 2/11 to follow-up (18.18%). Inter-rater agreement was 0.98.
3.3. Quality Indicator Comparison between Spanish Areas and Europe
The BC QI reporting was varied (Figure 2). The QI mean in each document was
11.00 (standard deviation: 10.59), ranging from 0 to 30 QIs reported. The clinical pathways
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or integrated breast cancer care processes that collected more QIs were EUSOMA’s [2]
with 34 QIs, Catalonia’s [34] with 30 QIs, and the government of Spain´s [29] with 28 QIs.
Asturias [32], Extremadura [35], Madrid [38], Basque Country [41], and Valencia [42] did
not register any QI.
Comparing the Spanish quality documents and the EUSOMA position paper [2], all
the clinical pathways and integrated cancer care processes that collected any BC QI had at
least one EUSOMA QI included. The national Spanish program [29] was the document
that collected more EUSOMA QIs (12 QIs), followed by the Catalonian program [34]
with 10 QIs.
No indicator appeared in all the 16 documents studied. Of the 51 indicators that
appeared only in the Spanish documents, “proportion of BC patients to be discussed pre-
and postoperatively by a multidisciplinary team (MDT)” and “proportion of invasive
cancer and clinically negative axilla cases who underwent sentinel lymph node biopsy
(SLNB) only (excluding primary systemic treatment or PST cases)” were the two QIs best
reported, appearing in up to 6/15 different documents [29–31,34,36,39].
The variability of the same QI among the diverse Spanish papers analysed is registered
in Figures 3 and 4. A total of 22/66 (33.33%) process and outcome QIs (12/53; 22.64%
related to the process and 10/13; 76.92% outcome QIs) did not express any standard
(Figure 3); the structure indicators do not present standards.
Concerning diagnosis, “proportion of BC cases who preoperatively underwent breast
and axilla radiology and physical examination” appeared in three documents [29,34,37]
that agree with a standard of 90%. “Proportion of BC cases for which prognostic and
predictive parameters have been recorded” should be more than 100% [34], compared
with EUSOMA’s [2] recommendation of 95%. “Proportion of patients with invasive can-
cer who underwent image-guided axillary staging” should be in all the cases at more
than 85% [2,29,34,39], while “proportion of patients with clinical history and/or staging
documented” might be 100% [29,34,39]. “Proportion of BC patients to be discussed pre-
and postoperatively by a MDT” varied from 90% recommended by EUSOMA [2] and
Andalusia [30] to 100% supported by the Spanish national document [29], Aragon [31],
Catalonia [34], Galicia [36], and Murcia [39].
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Quality indicators in breast
cancer care: An update from the
EUSOMA working group.
EUSOMA 2017 EUSOMA Europe Review, consensus Yes Not applicable Yes
2
Evaluación de la práctica
asistencial oncológica.





de Salud Spain Consensus No Yes Yes
3 Proceso Asistencial IntegradoCáncer de Mama (PAICM). Andalusia 2011 Junta de Andalucía Europe/Spain/Andalucía Review Yes Not applicable Yes
4 Proceso de Cáncer de Mama.Criterios de implantación. Aragon 2006
Sistema de Salud
de Aragón Europe/Spain/Aragón Consensus Yes Not applicable Yes




Europe/Spain/Asturias Not applicable No No No






and Leon Review No No Yes
7
Desarrollo de indicadores de
proceso y resultado, y
evaluación de la práctica
asistencial oncológica.
Catalonia 2006 Generalitatde Catalunya Europe/Spain/Catalonia Review, consensus No Yes Yes
8 Plan integral contra el cáncer enExtremadura. Extremadura 2017
Junta de
Extremadura Europe/Spain/Extremadura Not applicable No No No
9 Proceso asistencial integrado decancer de mama. Galicia 2014 Xunta de Galicia Europe/Spain/Galicia Not specified Yes Not applicable Yes
10 III plan de Salud La Rioja(2015–2019). Rioja 2015 Gobierno de La Rioja Europe/Spain/ La Rioja
Based on the Nation Plan
of Healthcare No No Yes
11
Plan integral de control del
cáncer de la Comunidad
de Madrid.
Madrid 2007 Comunidadde Madrid Europe/Spain/Madrid Not applicable No No No
12 Esta garantizada la calidad de laatención al cancer de mama. Murcia 2012 Región de Murcia Europe/Spain/Murcia
Based on the Nation Plan
of Healthcare Yes Not applicable Yes
13 Plan de Salud de Navarra. Navarra 2014 Gobiernode Navarra Europe/Spain/Navarra Not applicable No No No
14 Plan oncológico de Euskadi. Basquecountry 2018 Gobierno Vasco
Europe/Spain/
Basque Country Not applicable No No No
15
Estrategia contra el cancer de la
Comunitat Valenciana
2019–2022.
Valencia 2019 GeneralitatValenciana Europe/Spain/Valencia Not applicable No No No
Int. J. Environ. Res. Public Health 2021, 18, 6411 6 of 14




Figure 2. Appearance of the quality indicators (QIs) on diagnosis, staging, counselling, follow-up, and rehabilitation and 
others in the integrated BC health care process and clinical pathways analysed. QIs in bold were just published in EU-
SOMA. QIs in grey appeared in the Spanish documents analysed but not in the EUSOMA position paper. 
Figure 2. Appearance of the quality indicators (QIs) on diagnosis, staging, counselling, follow-up, and rehabilitation and
others in t i t r t lt c r r c ss cli ic l t s l s . Is i b l ere just published in EUSOMA.
QIs in grey app ared in the Spanish documents analysed but not in the EUSOMA positi n paper.
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Figure 3. Comparison of the standards of the breast cancer care quality indicators related to the process among the Spanish integrated breast cancer health care processes and clinical 
pathways analysed. NS in grey means “standard not specified”. 
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1 Proportion of patients who time elapsed from the Breast Pathology Unit's referral will not exceed X days. 3 days (ST= 85%) 15 days (ST= 100%)
2 Proportion of patients from breast cancer (BC) screening. NS NS
3 Proportion of patients with suspected BC who have done radiological studies in a single act. 90 %
4 Proportion of  BC cases who preoperatively underwent breast and axilla radiology and physical examination. 90 % 90 % 90 % 90 %
5 Proportion of BC patients which time elapsed from the request to the mammography will not exceed X days or weeks. 4 days (ST= 85%)
6 Time elapsed from the beginning of the process to the confirmation of BC diagnosis is X days or weeks. 7-14 days (ST= 85%) 10 days (ST=90%) 15 days (ST=90%)
7 Proportion of patients with BC who had a preoperative histologically or cytologically confirmed malignant diagnosis (B5 or C5). 85 % 90% 100 %
8 Time elapsed from the biopsy to obtain the pathology report will be less than X days. 10 days (ST=100%) 7 days (ST=100%) 5 days (ST=100%)
9 Proportion of BC cases for which prognostic and predictive parameters have been recorded. 95 % NS 100 %
10 Proportion of patients with invasive cancer who underwent image-guided axillary staging. 85 % 85 % 85 % 85 %
11 Proportion of benign to malignant diagnoses based on definitive surgical pathology report. 1:04
12 Proportion of patients with clinical history and /or staging documented. 100 % 100 % 100 %
13 Time elapse from surgery to final immunohistochemical diagnosis. NS
14 Percentage of reports with diagnosis, TNM stage, and therapeutic plan in relation to the total of reports issued. 100 % NS NS 100 %
15 Proportion of BC patients to be discussed pre and postoperatively by a multidisciplinary (MDT). 90 % 100 % 90 % 100 % 100 % 100 % 100 %
16 Proportion of professionals with participation in the MDT. NS
17 Proportion of BC diagnosis with a time elapsed from referral to decision-making by MDT less than 30 days. 100 % 100 % 100 %
18 Proportion of BC cases with less than 7 days from diagnosis's pathological confirmation until MDT evaluation. 100 %
19 Time elapsed from MDT decision until the start of the treatment should be 15 days. 90% 90%
20 Proportion of BC cases referred for genetic counselling. 10 % NS
21 Proportion of BRCA genetic determinations performed. NS
22 Diagnostic-therapeutic interval less than 28 days. 90 % 80 % 90 %
23 Proportion of patients with inflamatory BC or locally advanced non-resectable ER-carcinoma who received primary systemic treatment (PST). 90 %
24 Time elapsed between PST and surgical treatment. 90 %
25 Proportion of BC patients who undergo surgery within less than 30 days after the MDT decision. 90 % 90 % 90 % 90 % 90 %
26 Proportion of BC patients who undergo surgery within less than 30 days after surgical waiting list inclusion. 100 %
27 Proportion of BC cases referred from the Breast Unit to the Pre-anesthesia consultation in less than 7-10 days. 85 %
28 Proportion of BC patients with BCT. 50-80% 50-80% 50-80% 50-80% NS
29 Proportion of BC patients with invasive cancer not greater than 3 cm who underwent BCT as primary treatment. 70 %
30 Proportion of BC patients with in situ carcinoma  less than 2 cm who underwent BCT. 80 %
31 Proportion of BC patients (DCIS only) who received just one operation (excluding reconstruction). 80 % NS
32 Proportion of BC patients with a surgical safety check-list. 100 %
33 Proportion of BC patients with delayed reconstruction time less than 9 months. 85 %
34 Proportion of IC and clinically negative axilla cases who underwent SLNB only (excluding PST cases). 90 % NS NS NS NS NS NS
35 Proportion of BC patients with invasive cancer who underwent SLNB with no more than 5 nodes excised. 90 % NS
36 Proportion of BC patients with lymphadenectomy. NS NS NS
37 Proportion of patients with ductal in situ carcinoma only who do not undergo axillary clearance 97 %
38 Proportion of BC reinterventions in breast conserving therapy (BCT). NS NS
39 Proportion of BC reinterventions before 6 weeks for margin widening after BCT. < 15%
40 Proportion of BC patients who start adjuvant treatment in less than X days/weeks from the surgical intervention date. 6 weeks (ST=90%) 6 weeks (ST=90%) 10 days (ST=85%) 6 weeks (ST=90%) 6 weeks (ST=90%)
41 The delay time from the decision to place the subcutaneous catheter until placement will be less than 7 days. 85 %
42 Percentage of BC hormone treatment. 85 % 100 % 100 % NS 100 %
43 Proportion of HER2+ invasive cancer (T > 1 cm or N+) treated with chemotherapy who received adjuvant trastuzumab. 85 %
44 Proportion of patients with invasive cancer (M0) who received postoperative radiotherapy (RT) after BCT and sentinel lymph node bipsy (SLNB). 90 % 100 %
45 Proportion of BC patients with less than X days/weeks of delay from the RT indication to its initiation. 15 days (ST= 85%)
46 Proportion of BC patients who have direct access to a breast care nurse specialist. 95 % 100 %
47 Proportion of BC hospitalized patients with NANDA  terminology coded care plan in the discharge report. 100 %
48 Proportion of BC patients with immediate access to psychological support. NS NS NS NS
49 Time elapsed from the rehabilitation prescription to beginning will be less than 30 days. 85 %
50 Proportion of BC patients with a single final report with all the oncological strategy of their process. NS NS
51 Proportion of BC patients with a coordinated follow-up. NS
52 Proportion of BC patients included in the palliative care assistance process. NS







Figure 3. Comparison of the standards of the breast cancer care quality indicators related to the process among the Spanish integrated breast cancer health care processes and clinical
pathways analysed. NS in grey means “standard not specified”.
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Regarding treatment, “proportion of BC patients with breast-conserving therapy
(BCT)” did not arise in EUSOMA, but it was treated in a third part of the Spanish quality
care papers (5/15). All of these documents except one [29,30,34,39] stated a standard of
50–80% [40]. The “percentage of BC hormone treatment” standard was always 100% in the
Spanish documents [29,34,39], but 85% in the EUSOMA position paper. “All the patients
with invasive cancer (M0) who received postoperative radiotherapy after breast-conserving
surgery and SLNB” might be 100% [36], in contrast with only 90% in EUSOMA [2].
Analysing outcome QIs, the “proportion of BC patients receiving immediate recon-
struction” standard was more than 50% in Andalusia [39] versus 40% in EUSOMA [2].
Finally, “proportion of BC cases with lymphedema or without recovery of shoulder mobility
referred to rehabilitation” should be 80% in Navarra [40] versus 100% in Catalonia [34].
3.4. Shared Decision Making as an Essential Quality Indicator
We studied the appearance of SDM in the integrated cancer care processes and clinical
pathways analysed. Only Castile and Leon [33] and Navarra [40] admitted its importance
(see Figure 2). Navarra highlighted the importance of involving at least 15% of the patients
in the BC care management decision. No other QIs about SDM use or measures were found.
3.5. Quality Indicators about Timing Processes
Figure 3 refers to all the indicators about timing in grey, followed by the standard
established by the different quality care documents. Some of them are noteworthy in the
following text. The QIs not mentioned are analysed in Figure 4. There were 18 QIs about
the timing process, and only 1 (0.05%) did not state any standard.
Concerning diagnosis, “proportion of patients who time-elapsed from the breast
pathology unit’s referral should not exceed 3 days [31] or 15 days” [36] depending on the
quality care document with a standard that varied from 85% to 100%. The “time elapsed
from the beginning of the process to the confirmation of BC diagnosis should be 7–14 or
10 days” standard varied from 90% or 85%, respectively [31,36]. “Time elapsed from the
biopsy to obtain the pathology report will be less than 5 [36], 7 [34], or 10 [31] days”, and
the “BC diagnosis should be referral to MDT in less than 30 days” [30,34,36] in both cases
with a standard of 100%.
Regarding treatment, the “diagnostic–therapeutic interval must be less than 28 days”
in more than 80% [34] to 90% [29,39] of the BC patients. The “proportion of BC patients
who undergo surgery within less than 30 days after the MDT decision” QI, although it did
not appear in EUSOMA, reached the highest consensus with a five-document agreement
standard of 90% [29–31,34,39]. Finally, the “proportion of BC patients who start adjuvant
treatment in less than a specific date from the surgical intervention date” QI had an
enormous variability. Four quality care documents’ [29,30,34,39] standard was 90% in
6 weeks, but Aragon’s [31] clinical pathway stated 85% in 10 days.
4. Discussion
4.1. Main Findings
No systematic reviews were found in our search for Spanish health care QIs collected
from integrated health care processes or clinical pathways. Only one-tenth of the indicators
appeared exclusively in EUSOMA [2], including only 4 out of 10 of the QIs identified.
There was heterogeneity among the QIs. No single indicator appeared in all the documents
studied, and there was an enormous variability in QI descriptions. Over three-quarters were
QIs dedicated to diagnosis and treatment, and the majority were process related. The QIs
collected mostly were “proportion of BC patients to be discussed pre- and postoperatively
by an MDT” and “proportion of invasive cancer and clinically negative axilla cases who
underwent SLNB only (excluding PST cases)”. A third of the process and outcome QIs did
not state a standard for reference.
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4.2. Strengths and Weaknesses
To our knowledge, a collation of BC care management QIs has not been published
before. We undertook a comprehensive systematic review with many expert reviewers
studying an important number of integrated BC assistance processes and clinical pathways.
This review provided a powerful insight into the state of QIs for the whole BC care
management process, including diagnosis, treatment, and follow-up.
The data extraction’s subjective character was addressed using three qualified and
trained BC specialist clinicians. The reviewers held a consensus meeting to consolidate
criteria before duplicate data extraction appraisal. A fourth reviewer arbitrated the work
to get a consensus when a meaningful deviation among the reviewers appeared. The ICC
was higher than 98%, denoting an excellent reviewer agreement.
A possible limitation was to compare the Spanish clinical pathways or integrated
breast cancer assistance processes versus the EUSOMA position paper [2]. The Spanish
documents covered all the phases required in the BC care management process, from the
general practitioner’s referral to the follow-up, while the European document was directed
to the specific BC unit of care. However, this could be considered an advantage as including
these Spanish manuals has shown the necessity for adding all levels and aspects of care in
BC quality assessment.
One limitation could be geographical in that only Spanish documents were assessed
in this review. However, our main objective was to highlight the level of consensus when
choosing QIs of an important disease such as BC in the same country. Our findings
emphasised the importance and urgent need for agreement about this issue. A strong
point of this systematic review is that our team included researchers competent in both the
English and Spanish languages. There was no need to use external translations to interpret
any report.
Most of the studied papers were not academic articles in scientific journals or indexed
in databases. Although it was not easy, a comprehensive manual search of grey literature
was conducted to find administrations and official institutions engaged in BC care manage-
ment quality on the World Wide Web. We engaged expert reviewers in this clinical field
to ensure that we captured the totality of the relevant literature. We also searched in the
identified publications’ bibliographies to incorporate more studies into our review. An
interesting observation is that we did not find any document in order to analyse QIs in
only three Spanish areas.
4.3. Implications
Our systematic review offers a crucial contribution to BC care quality assessment. It
presents an extensive study of all the available BC care QIs in Spain and highlights relevant
discrepancies among the studied integrated health care processes and clinical pathways.
It provides a global overview of the current situation of the QIs by identifying areas in
need of urgent improvement. Medical improvements are occurring quickly, so continuous
development and periodic updates are needed. The BC care process’s control and progress
could be made by analysing a single set of QIs and would help correlate results with other
centres so stronger conclusions could be obtained [3].
The physical environment or structure is imperative in influencing the health care
delivery process and outcomes. This physical environment will require supporting staff
plus a healing environment to conclude better quality care finally [43].
Nowadays, even though diverse institutions have published different indicators to
assess BC care quality, there is yet no consensus on BC QIs even in the same country [15,44].
Hence, correlation among studies is challenging, and this reduces the feasibility of compar-
ing outcomes among different hospitals or health care areas [3]. Sometimes the same QIs
could be interpreted as measuring different aspects of care [45]. Quality is a wide concept
that needs a range of QIs to analyse various dimensions of care.
Even though only a few indicators have appeared exclusively in EUSOMA [2], it
should be noted that the Spanish documents have not collected indicators about the use of
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magnetic resonance imaging in BC care, nurse counselling, and follow-up. These EUSOMA
indicators should be reviewed and added to them in the next updates. On the other hand,
the Spanish documents provided many indicators that EUSOMA did not collect, but no
indicators were found about primary care or patient satisfaction. The European position
paper [2] indicates that more studies are necessary to establish satisfaction indicators, but
it does not consider indicators related to primary care. Obtaining QIs at all breast cancer
care levels should be highlighted as an important point of improvement to control and
improve cancer quality care and not only focus on breast units. All the links in the chain
are important to obtain excellent results. Besides, SDM, a recognised pillar of high-quality
cancer care, was vaguely included in only two documents. Forthcoming reviews should
give deep consideration to primary care, patient satisfaction, and SDM.
A minimum standard of quality care is beneficial to evaluate compliance and the
necessity for improvement. In this review, we found proposed standards for two-thirds of
the process and outcome indicators, but there was high variability among documents. For
example, most of the documents proposed that adjuvant treatment should start in 6 weeks
in 90% of the patients, but only one document set 10 days in 85% of the patients [31].
Evidence indicates that the ideal time to start treatment is 4–8 weeks, permitting recovery
from surgery. A longer delay could be associated with worse outcomes and increased
mortality [46] due to the rapid growth of micrometastasis following the removal of the
primary tumour [47]. Therefore, all the QIs should be evidence based.
Further research and consensus regarding the best BC QIs and standards for improv-
ing quality is needed and deserves immediate consideration. There is an urgent need
for a compendium of common QIs and their standards of care for all the autonomous
communities in Spain. Each region should design specific QIs, taking into account the
particular characteristics of its population. Thus, a set of common and specific QIs should
be developed to allow a homogeneous analysis of the BC quality of care and comparisons
among regions.
5. Conclusions
There is no consensus concerning BC care QIs and standards in Spain, and QI focus
on primary care, patient satisfaction, and SDM is lacking. Although a majority of the QIs
established a standard, they were very varied. These differences made comparisons among
different health care providers arduous, decreasing the chance of making reasonable
comparisons. There is an urgent need for establishing an agreed set of BC care QIs.
Common and specific QIs should be developed to allow a homogeneous analysis of the BC
quality of care and comparisons among regions.
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Appendix A. Data Sources and Search Strategy
Appendix A.1. Sample Search Strategy for Medline
A systematic search was conducted on 19 February 2021 in Medline (via PubMed, to
February 2021) using the following combination of free-text terms:
#1 breast cancer (all)
#2 breast neoplasms (all)
#3 quality indicators (all)
#4 quality care (all)
#5 2010 (pdta): 3000 (pdta)
# #6 AND #10 AND #11 AND #12
Results: 7 articles
Appendix A.2. Online Databases
1. Embase
2. Scopus
3. Web of Science
4. Medline
Appendix A.3. Websites of European Institutions
1. EUSOMA, Europe
2. Professional institutions and societies or governmental agencies from Spain
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